68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Status Not yet recruiting

Clinical Trial Summary

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02038738
Study type	Interventional
Source	Ochsner Health System
Contact	Richard J. Campeau, M.D.
Phone	504-464-8500
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	March 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01642251` - Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT04069299` - Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
Recruiting	`NCT04464122` - Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Recruiting	`NCT04325425` - Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary	Phase 2
Completed	`NCT03834701` - Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms	N/A
Recruiting	`NCT03279614` - Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma	Phase 2
Recruiting	`NCT05978284` - Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma	Phase 1/Phase 2
Recruiting	`NCT05076786` - Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma	Phase 2
Completed	`NCT00388063` - Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma	Phase 2
Withdrawn	`NCT03901378` - Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma	Phase 2
Recruiting	`NCT02970786` - Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans	Phase 1
Completed	`NCT00663429` - Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma	Phase 2
Recruiting	`NCT05113355` - Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm	Phase 2
Completed	`NCT03278405` - Avelumab in G3 NEC	Phase 1/Phase 2
Active, not recruiting	`NCT03837977` - Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma	Phase 2
Recruiting	`NCT06372626` - Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.	Phase 1/Phase 2
Not yet recruiting	`NCT06333314` - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI	Phase 2
Active, not recruiting	`NCT02687958` - Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin	Phase 2
Completed	`NCT01121939` - Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers	Phase 2
Recruiting	`NCT03168607` - Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma	Phase 2